Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Garsorasib in advanced NSCLC
NCT05383898Phase 2Completed
- Sponsor
- InventisBio
- Start
- Mar 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of garsorasib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by InventisBio. Primary endpoints: Incidence of Dose-limiting toxicities at 21 days, Number of participants with adverse events at 3 years and 1 more. Started Mar 2021; status: completed.
02
Drugs
garsorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05383898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05383898.